Allcutis Research Inc — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,163	1
2024	Research	$6,532	2
2023	Research	$9,473	5
2022	Research	$5,513	5
2021	Research	$280,160	45
2020	Research	$144,216	9

Breakdown

Who paid Research payments · program years 2020–2025

Eli Lilly and Company $318,624 34 payments
Ucb SA $81,071 30 payments
Dermira, Inc. $47,362 3 payments

Studies the money was for Research payments · program years 2020–2025

A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $143,231 7 payments
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $100,861 6 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3041658 in Adults With Moderate-To-Severe Hidradenitis Suppurativa $49,095 11 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $37,837 15 payments
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $33,037 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $31,853 8 payments
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $14,325 1 payment
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $12,519 3 payments
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $11,381 7 payments
An Open-Label 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color $7,935 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.